ClinicalTrials.gg
CompletedNCT03531320Updated Nov 24, 2023Results posted

Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase

A Phase 1/2 interventional study of D07001-softgel capsules in Gastrointestinal Cancer and Biliary Tract Cancer, sponsored by InnoPharmax Inc.. Completed at 4 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by InnoPharmax Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Gastrointestinal Neoplasms with a site in Taiwan — 8 open to participants now, 14 under way, 4 of them phase 3. Gastrointestinal Neoplasms · Taiwan.

Enrollment
20th of 21
19 · median 222
Started
2018
the only one that year
Phase 1/2
6 of 25
2 open now
Registered
9th of 25
by date

Among the 25 studies in Gastrointestinal Neoplasms with a site in Taiwan, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 1/2, and was the 9th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

8 of the 25 studies in Gastrointestinal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Gastrointestinal Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI) cancer.

Part 2: Dose-Expansion Phase (Phase 2) The primary objective is to assess the safety and tolerability of D07001 softgel in patients who have achieved stable disease or better following first line chemotherapy or combined chemoradiotherapy (CCRT) for unresectable metastatic or locally advanced biliary tract cancer (BTC)

Read the detailed description

This open label, multicenter study will be conducted in 2 parts: a dose-escalation phase (Part 1) and a dose-expansion phase (Part 2).

In both Part 1 and Part 2, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle).

Part 1: Dose Escalation Phase (Phase 1b) Part 1 of the study will follow a 3+3 dose escalation scheme at predefined dose levels. There will be sequential cohorts of 3 to 6 patients each with increasing doses of 40 mg, 60 mg, 80 mg, 120 mg, and 160 mg per cohort. There will be no intra patient dose escalation. Cycle 1 (21 days) is defined as the dose limiting toxicity (DLT) assessment period.

Part 2: Dose Expansion Phase (Phase 2) In Part 2 of the study, eligible patients will be randomized in a 1:1 ratio to receive D07001-softgel in an open label manner at 1 of the 2 dose levels selected for expansion. Twenty (20) patients will be enrolled to each dose expansion cohort. Patients will be treated until withdrawal from treatment due to disease progression according to RECIST v1.1, withdrawn consent, or when another treatment discontinuation criterion is met. Patients who are discontinued from study drug for reasons other than disease progression or toxicity in the first 2 cycles of Part 2 will be replaced.

03

Conditions studied

  • Gastrointestinal Cancer
  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of a signed and dated written Form (ICF) prior to any study specific procedures
  2. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan)
  3. Histopathological or cytologic diagnosis of unresectable, or locally advanced GI cancer (Part 1) or unresectable metastatic or locally advanced BTC (cholangiocarcinoma or gallbladder cancer; Part 2)
  4. Part 1 only: to or have relapsed from all standard therapies of advanced GI
  5. Part 2 only:

    1. Achieved stable disease or better, based on the Investigator's assessment, in response to systemic therapy or CCRT, with continued stable disease or better based on imaging studies obtained as part of screening
    2. Completed first line systemic therapy (with 2-8 cycles of chemotherapy with a gemcitabine based regimen) or CCRT, based on the local standard of care and preferences in the participating countries Note: No more than 30% of patients enrolled in Part 2 will have received CCRT
  6. No more than 60 days have elapsed between completion of the prior line of chemotherapy or CCRT and enrollment
  7. Part 2 only: Patient has not received intervening systemic therapy since first line treatment
  8. (ECOG) Performance Status (PS) of 0-2 in Part 1 and 0-1 in Part 2
  9. is >12 weeks
  10. Adequate bone marrow function, demonstrated by:

    1. (ANC) ≥1,500 cell/mm3
    2. count ≥100,000 cells/mm3
    3. ≥9 g/dL
  11. Adequate liver function, demonstrated by:

    1. (AST) and alanine transaminase (ALT) ≤2.5 x (ULN), or ≤5.0 x ULN in the case of liver metastases
    2. Total ≤1.5 x ULN
    3. Albumin ≥3.0 g/dL
    4. (INR) \<1.5
  12. Adequate renal function, demonstrated by:

    1. Serum creatinine ≤1.5 x ULN
    2. ≥ 60 mL/min calculated by Cockcroft-Gault formula or directly measured with 24 hr urine collection
  13. If a woman of , the patient has a negative serum pregnancy test at screening and is not breastfeeding
  14. If a woman of childbearing potential, patient must use a medically acceptable form of as 2 barrier methods (e.g., combination of condom, diaphragm, or intrauterine device), hormonal contraception (estrogen or progesterone agents) or 1 barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male patients must adhere to the same birth control methods.
  15. Patient is willing to comply with protocol-required visit schedule and visit requirements

Exclusion criteria

Exclusion Criteria:

  1. Part 2 only: More than one prior chemotherapy regimen for unresectable or locally advanced BTC Note: prior radiation (with or without radiosensitizing doses of chemotherapy) or fluoropyrimidine chemotherapy are allowed as postsurgical therapy.
  2. Part 2 only: Received any systemic therapy (chemotherapy, biologics, immunotherapy, or agents) for metastatic disease other than gemcitabine based chemotherapy or CCRT for locally advanced BTC
  3. Diagnosis of active (other than GI cancer [Part 1] or BTC [Part 2]) within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent
  4. Prior discontinuation of gemcitabine because of pulmonary or hepatic toxicity or hemolytic uremic syndrome (HUS) or , allergic reaction, or intolerance
  5. Any GI disorder which would significantly impede absorption of an oral agent
  6. Known brain or
  7. Surgery or radiation therapy within the past 28 days
  8. Part 2 only: Evidence of disease progression, based on the Investigator's assessment, on the screening computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
  9. Any active disease or condition that would not permit compliance with the protocol
  10. Residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted)
  11. cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, or [NYHA] Grade 2 or greater), or uncontrolled serious cardiac arrhythmia
  12. Patient has a history of drug or alcohol abuse within last year
  13. Patient has documented cerebrovascular disease
  14. Patient has a seizure disorder not controlled on medication (based on decision of Investigator)
  15. Patient received an investigational agent within 28 days of enrollment
  16. Patients with uncontrolled active viral, bacterial, or systemic fungal infection
  17. Patient has known (HIV) infection
  18. Patient has virus (HBV) and/or virus (HCV) infection in medical history. If positive results are not indicative of true active or chronic infection, the patient can enter the study after discussion and agreement between the Investigator and the Clinical Research Organization (CRO) Medical Monitor
  19. Patient has received yellow fever vaccine or other (s) within the 4 weeks prior to screening
  20. Patient has any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in, and compliance with, a clinical trial
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Part 1:Dose-Escalation Phase

    40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules

    Drug: D07001-softgel capsules

  • Experimental
    Part 2: Dose-Expansion Phase (Phase 2)

    higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules

    Drug: D07001-softgel capsules

Interventions

  • DrugD07001-softgel capsules

    Active Ingredient:Gemcitabine hydrochloride

06

What researchers measure

Primary outcomes

  1. Part 1: Establish the Maximum Tolerated Dose (MTD)

    MTD will be defined based on the number of dose limiting toxicities (DLT) in subjects at each dose level. DLT definition: In Part 1 of the study, any of the following AEs occurring during Cycle 1 will be classified as DLTs, if there is a reasonable possibility that it is related to the study drug * Hematologic: * Grade 4 neutropenia lasting \>7 days * Febrile neutropenia (defined as neutropenia Grade ≥3 and a body temp ≥38.3°C) * Grade ≥3 neutropenic infection * Grade 4 anemia * Grade ≥3 thrombocytopenia with bleeding * Grade 4 thrombocytopenia * Non-hematologic: o Grade ≥3 toxicities that are considered clinically significant, except those that have not been maximally treated (e.g., nausea, vomiting, diarrhea\*) or can be easily treated (e.g., electrolyte abnormalities). * Failure to deliver at least 6 of the planned 9 doses during Cycle 1 due to treatment-related toxicities. * Upon the second occurrence of a toxicity leading to a dose hold.

    Time frame: During Cycle 1 of treatment (each cycle is 21 days) for each subject

  2. Part 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)

    AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

    Time frame: From date of informed consent to 30-day follow-up visit for each subject, an average of 10 months

  3. Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug

    To measure ratio of total subjects who experienced the dose modifications including dose reduction, interruption, or discontinuation of study drug due to AEs.

    Time frame: First dose through last dose for each subject, an average of 8 months

Secondary outcomes

  1. Part 1: Pharmacokinetics (PK)- Cmax

    PK would be analyzed by maximum concentration (Cmax) of dFdC

    Time frame: Cycle 1 Days 1 and 15

  2. Part 1: PK- AUC

    PK would be analyzed by Area Under Curve (AUC) of dFdC

    Time frame: Cycle 1 Days 1 and 15

  3. Part 2: Pharmacokinetics (PK)- Cmax

    PK would be analyzed by maximum concentration (Cmax) of dFdC

    Time frame: Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only

  4. Part 2: PK- AUC

    PK would be analyzed by Area Under Curve (AUC) of dFdC

    Time frame: Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only

07

Results

Posted Nov 24, 2023

Participant flow

Participant flow — Overall Study
MilestonePart 1:Dose-Escalation Phase_40mgPart 1:Dose-Escalation Phase_60mgPart 1:Dose-Escalation Phase_80mgPart 1:Dose-Escalation Phase_120mgPart 1:Dose-Escalation Phase_100mg
Started43363
Completed33363
Not completed10000

Outcome measures

PrimaryPart 1: Establish the Maximum Tolerated Dose (MTD)

MTD will be defined based on the number of dose limiting toxicities (DLT) in subjects at each dose level. DLT definition: In Part 1 of the study, any of the following AEs occurring during Cycle 1 will be classified as DLTs, if there is a reasonable possibility that it is related to the study drug * Hematologic: * Grade 4 neutropenia lasting \>7 days * Febrile neutropenia (defined as neutropenia Grade ≥3 and a body temp ≥38.3°C) * Grade ≥3 neutropenic infection * Grade 4 anemia * Grade ≥3 thrombocytopenia with bleeding * Grade 4 thrombocytopenia * Non-hematologic: o Grade ≥3 toxicities that are considered clinically significant, except those that have not been maximally treated (e.g., nausea, vomiting, diarrhea\*) or can be easily treated (e.g., electrolyte abnormalities). * Failure to deliver at least 6 of the planned 9 doses during Cycle 1 due to treatment-related toxicities. * Upon the second occurrence of a toxicity leading to a dose hold.

Time frame:
During Cycle 1 of treatment (each cycle is 21 days) for each subject
Reported as:
Number · mg
Part 1: Establish the Maximum Tolerated Dose (MTD)
mgPart 1:Dose-Escalation Phase
Part 1: Establish the Maximum Tolerated Dose (MTD)100
PrimaryPart 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)

AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

Time frame:
From date of informed consent to 30-day follow-up visit for each subject, an average of 10 months
Reported as:
Number · participants
Part 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)
participantsPart 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5
Related to study drug SAEs00021
Related to study drug AEs22363
DLTs00020
PrimaryPart 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug

To measure ratio of total subjects who experienced the dose modifications including dose reduction, interruption, or discontinuation of study drug due to AEs.

Time frame:
First dose through last dose for each subject, an average of 8 months

No measurements were reported for this outcome.

SecondaryPart 1: Pharmacokinetics (PK)- Cmax

PK would be analyzed by maximum concentration (Cmax) of dFdC

Time frame:
Cycle 1 Days 1 and 15
Reported as:
Mean · ng/mL
Part 1: Pharmacokinetics (PK)- Cmax
ng/mLPart 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5
Cycle 1 Day 113.67 ± 7.5842.97 ± 27.147.37 ± 5.6837.24 ± 23.8424.05 ± 17.43
Cycle 1 Day 1514.45 ± 13.9312.93 ± 2.8410.66 ± 9.1518.47 ± 13.3113.28 ± 7.92
SecondaryPart 1: PK- AUC

PK would be analyzed by Area Under Curve (AUC) of dFdC

Time frame:
Cycle 1 Days 1 and 15
Reported as:
Mean · h*ng/mL
Part 1: PK- AUC
h*ng/mLPart 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5
Cycle 1 Day 112.35 ± 7.1241.14 ± 4.4211.59 ± 8.8362.79 ± 42.1054.40 ± 44.19
Cycle 1 Day 1512.71 ± 13.0719.50 ± 3.7414.05 ± 10.3035.20 ± 33.2936.96 ± 31.35
SecondaryPart 2: Pharmacokinetics (PK)- Cmax

PK would be analyzed by maximum concentration (Cmax) of dFdC

Time frame:
Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only

No measurements were reported for this outcome.

SecondaryPart 2: PK- AUC

PK would be analyzed by Area Under Curve (AUC) of dFdC

Time frame:
Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only

No measurements were reported for this outcome.

Adverse events

Collected over The Adverse event information was collected and assessed in relation to baseline for study patients from the first dose of treatment until 30 days after discontinuation of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1:Dose-Escalation Phase Level 10/4 (0%)0/4 (0%)2/4 (50%)
Part 1:Dose-Escalation Phase Level 20/3 (0%)0/3 (0%)2/3 (66.7%)
Part 1:Dose-Escalation Phase Level 30/3 (0%)0/3 (0%)3/3 (100%)
Part 1:Dose-Escalation Phase Level 40/6 (0%)2/6 (33.3%)6/6 (100%)
Part 1:Dose-Escalation Phase Level 50/3 (0%)1/3 (33.3%)3/3 (100%)
Part 2: Dose-Expansion Phase (Phase 2)———
Most frequent serious events
Most frequent serious events
EventPart 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Part 2: Dose-Expansion Phase (Phase 2)
DiarrhoeaGastrointestinal disorders0/40/30/30/61/3—
hepatotoxicityHepatobiliary disorders0/40/30/31/60/3—
FeverGeneral disorders0/40/30/31/60/3—
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPart 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Part 2: Dose-Expansion Phase (Phase 2)
NauseaGastrointestinal disorders1/40/31/33/62/3—
VomitingGastrointestinal disorders0/40/31/34/60/3—
FaitigueGeneral disorders0/40/32/34/61/3—
FeverGeneral disorders0/40/31/32/61/3—
AnorexiaMetabolism and nutrition disorders1/41/31/32/61/3—
DiarrhoeaGastrointestinal disorders0/41/30/32/61/3—
ChillsGeneral disorders0/40/30/32/60/3—
MalaiseGeneral disorders0/40/31/31/60/3—
Alanine aminotransferase increasedInvestigations0/40/30/32/60/3—
Aspartate aminotransferase increasedInvestigations0/40/30/32/60/3—

Baseline characteristics

Total 19 subjects

Age, Continuous
Age, Continuous(years)Part 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Total
Mean67.8 ± 13.5257.7 ± 10.6954.7 ± 13.0155.5 ± 10.8855.7 ± 15.5058.3 ± 12.14
Sex: Female, Male
Sex: Female, Male(Participants)Part 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Total
Female101114
Male3325215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Total
Asian4336319
Region of Enrollment
Region of Enrollment(participants)Part 1:Dose-Escalation Phase Level 1Part 1:Dose-Escalation Phase Level 2Part 1:Dose-Escalation Phase Level 3Part 1:Dose-Escalation Phase Level 4Part 1:Dose-Escalation Phase Level 5Total
Taiwan4336319
08

Study locations

4 sites
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Cheng-Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Dec 2020, 28 months.

Results were first posted in Nov 2023, 2 years 10 months after primary completion.

Of 36 phase 1/2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2018
First posted
May 21, 2018
StartActual
Aug 6, 2018
Primary completionActual
Dec 28, 2020
CompletionActual
Dec 29, 2020
Results first posted
Nov 24, 2023
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03531320
Lead sponsor
InnoPharmax Inc.
Responsible party
Sponsor
First posted
May 21, 2018
Start date
Aug 6, 2018
Primary completion
Dec 28, 2020
Completion
Dec 29, 2020
Results posted
Nov 24, 2023
Last update
Nov 24, 2023

Study contacts

Li-Tzong Chen, Ph. D
principal investigator · National Cheng-Kung University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion